{"title":"The impact of different pulmonary rehabilitation approaches on fibrotic interstitial lung disease: a comparative randomized trial.","authors":"Esra Pehlivan, Erdoğan Çetinkaya, Fulya Senem Karaahmetoğlu, Zeynep Betül Özcan, Kürşad Nuri Baydili, Barış Demirkol, Halit Çınarka, Ramazan Eren, Amine Ataç","doi":"10.1080/17476348.2025.2513512","DOIUrl":"10.1080/17476348.2025.2513512","url":null,"abstract":"<p><strong>Background: </strong>Fibrosing Interstitial Lung Diseases (F-ILDs) lead to reduced exercise capacity and quality of life. Pulmonary Rehabilitation (PR) exercise programs have shown potential in improving symptoms and functional capacity in these patients. This study aimed to compare the effectiveness of different PR exercise approaches in patients with F-ILDs.</p><p><strong>Research design and methods: </strong>This randomized, three-arm controlled trial included F-ILD patients divided into three groups: hospital-based supervised(HGr), synchronized-online(SOGr) with live video calls, and video-based (VGr) with recorded exercise videos. All groups underwent an 8-week program combining aerobic and resistance training. Clinical parameters assessed included 6-minute walking distance(6MWD), modified medical research council dyspnea score(mMRC), respiratory function tests, Saint George Respiratory Questionnaire (SGRQ), International Physical Activity Questionnaire Short Form(IPAQ-SF), fatigue severity scale (FSS), and muscle strength.</p><p><strong>Results: </strong>Of the 75 patients, 65 completed the study, with comparable demographic and baseline characteristics. Significant improvements in 6MWD, mMRC, maximal inspiratory pressure, IPAQ-SF, SGRQ, and peripheral muscle strength were seen in all groups. Post-hoc analysis showed HGr had greater improvements in forced vital capacity and FSS compared to SOGr.</p><p><strong>Conclusion: </strong>Hospital-based, synchronized-online, and video-based PR programs all improve clinical outcomes in patients with F-ILDs. However, supervised in-hospital PR yielded greater benefits in lung function and fatigue reduction compared to the online approaches.</p><p><strong>Clinicaltrial registration: </strong>https://clinicaltrials.gov/study/NCT05166057.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1027-1035"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Helena Buso, Giulia A M L Costanzo, Nicola Monaco, Nicholas Landini, Davide Firinu, Marcello Rattazzi, Francesco Cinetto, Cinzia Milito
{"title":"An update on appropriate lung management in patients with primary antibody deficiencies.","authors":"Helena Buso, Giulia A M L Costanzo, Nicola Monaco, Nicholas Landini, Davide Firinu, Marcello Rattazzi, Francesco Cinetto, Cinzia Milito","doi":"10.1080/17476348.2025.2517299","DOIUrl":"10.1080/17476348.2025.2517299","url":null,"abstract":"<p><strong>Introduction: </strong>Predominantly antibody deficiencies (PADs) represent the most common inborn errors of immunity (IEIs), constituting over 50% of all IEIs detected globally. Compared to other IEIs, PADs are linked to a more favorable long-term prognosis and are typically diagnosed in adulthood. We analyzed the most recent literature on lung involvement in PAD using PUBMED Central.</p><p><strong>Areas covered: </strong>PADs are characterized by their impact on the respiratory system, which results in significant morbidity and mortality due to the impairment of both humoral and mucosal immune responses. This impact leads to a broad spectrum of complications that could be infection-related, inflammatory, or neoplastic.</p><p><strong>Expert opinion: </strong>Defined guidelines are unavailable, but a strict assessment of pulmonary status should be recommended in patients with characteristic immunologic patterns (low IgA serum level, reduced percentage of switched memory B cells, increased IgM serum levels, increased percentage of CD21 low B cells, autoimmune cytopenia, and splenomegaly).</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"981-996"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Respiratory post COVID sequelae: the role of pulmonary function impairment, fatigue and obesity in dyspnea and the impact of SPA rehabilitation.","authors":"Emanuela Resta, Chiara Noviello, Preethymol Peter, Giusi Graziano, Valeria Dalena, Alessia Caputi, Giorgio Castellana, Giacomo Riformato, Silvio Tafuri, Pierucci Pierucci","doi":"10.1080/17476348.2025.2516801","DOIUrl":"10.1080/17476348.2025.2516801","url":null,"abstract":"<p><strong>Background: </strong>Respiratory COVID-19 post-acute sequelae (PASC) may persist for extended periods following recovery.</p><p><strong>Methods: </strong>Patients with PASC who were referred for Salus Per Aquam (SPA) therapy were enrolled in the study.</p><p><strong>Aim: </strong>To categorize patients based on the presence of dyspnea and fatigue, with a specific focus on obesity, chronic respiratory conditions, and predictors of rehabilitation outcomes.</p><p><strong>Results: </strong>From July-November 2021, 327 consecutive patients were enrolled at the spa center. Among these, 31% had been previously hospitalized, 5% had required noninvasive or invasive mechanical ventilation. Approximately one-third of the cohort underwent DLCO testing, which was abnormal in 56.3% of cases. Patients with impaired DLCO had significantly higher dyspnea rates compared to those with normal DLCO (88.9% vs. 64.3%, <i>p</i> < 0.0001). Dyspneic patients were more likely to have one or more comorbidities (<i>p</i> < 0.001), be obese (<i>p</i> = 0.005), and have a history of chronic respiratory disease (<i>p</i> = 0.0009). Patients reporting fatigue also had higher rates of dyspnea (91.2% vs. 61.5%, <i>p</i> < 0.0001), were more frequently obese (<i>p</i> = 0.03), had more comorbidities (<i>p</i> = 0.02), and had a greater history of hospitalization (<i>p</i> = 0.02). No improvement in dyspnea/fatigue was observed post-SPA treatment among patients with DLCO impairment and obese. However, patients with chronic respiratory conditions reported benefit.</p><p><strong>Conclusions: </strong>Dyspnea in PASC is complex and multifactorial. The findings suggest that SPA rehabilitation may be particularly beneficial for alleviating fatigue and enhancing overall well-being in selected subgroups of patients with PASC.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1017-1026"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Louise Bondeelle, Guang-Shing Cheng, Anne Bergeron
{"title":"What's new in the management of pulmonary complications in allogeneic stem cell transplantation?","authors":"Louise Bondeelle, Guang-Shing Cheng, Anne Bergeron","doi":"10.1080/17476348.2025.2513519","DOIUrl":"10.1080/17476348.2025.2513519","url":null,"abstract":"<p><strong>Introduction: </strong>As survival increases after allogeneic hematopoietic stem cell transplantation (allo-HCT), several organ complications have emerged, including those involving the lung, which require a multidisciplinary management approach. The constant evolution of allo-HCT procedures, advances in diagnostic tools for infections and pulmonary disease, as well as new treatment approaches, require frequent updating of knowledge in this field.</p><p><strong>Areas covered: </strong>We review the multiple infectious and noninfectious lung complications that occur both early and late after allo-HCT. This includes an updated description of these complications, risk factors, diagnostic approach and outcome. A literature search was performed using PubMed-indexed journals.</p><p><strong>Expert opinion: </strong>The diagnosis of pulmonary complications after allo-HCT remains challenging, further complicated by the frequent association of co-infections and/or links between infection and noninfectious complications. The development of metagenomic next-generation sequencing (mNGS) should enhance the diagnostic yield of bronchoalveolar lavage, but its clinical relevance remains to be evaluated. A better understanding of the pathophysiology of the lung chronic graft-versus-host disease (GVHD) and improved phenotyping are essential for advancing its diagnostic and therapeutic management. This requires a revision of diagnostic criteria and the identification of new biomarkers of early disease.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"903-923"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Esther Solano-Pérez, Julia Oliva-Álvarez, Olga Mediano, Manuel Sánchez-de-la-Torre
{"title":"Predictive biomarkers of adequate response to continuous positive airway pressure treatment in sleep apnea: targeting cardiovascular outcomes.","authors":"Esther Solano-Pérez, Julia Oliva-Álvarez, Olga Mediano, Manuel Sánchez-de-la-Torre","doi":"10.1080/17476348.2025.2516809","DOIUrl":"10.1080/17476348.2025.2516809","url":null,"abstract":"<p><strong>Introduction: </strong>The management of obstructive sleep apnea (OSA) based solely on a single metric, the apnea-hypopnea index, constitutes a reductionist approach and has a significant limitation, as it does not adequately capture the multifactorial pathophysiology, phenotypic variability, and clinical heterogeneity of the disease.</p><p><strong>Areas covered: </strong>The heterogeneity observed in clinical presentations and treatment responses suggests the potential existence of distinct subpopulations in this condition. OSA has been linked to an increased cardiovascular (CV) risk, with continuous positive airway pressure (CPAP) as the primary treatment. However, treatment response varies among patients, highlighting the need for personalized therapeutic approaches. The identification of patients in whom CPAP therapy may mitigate CV risk in OSA could enhance personalized medicine for OSA.</p><p><strong>Expert opinion: </strong>The objective of this review was to provide a description of various metrics that have been explored in recent years and that may predict CV risk reduction with CPAP therapy. These metrics have been classified into potential molecular biomarkers and biosignals derived from sleep studies. This study describes the predictive role of these biomarkers in the identification of OSA subpopulations that can be protected from CV events using CPAP therapy.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"955-966"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eamon Mullen, Mark Murphy, Georgia Bateman, Michelle Casey, Cedric Gunaratnam, Noel G McElvaney
{"title":"An update on targeting airway inflammation in cystic fibrosis.","authors":"Eamon Mullen, Mark Murphy, Georgia Bateman, Michelle Casey, Cedric Gunaratnam, Noel G McElvaney","doi":"10.1080/17476348.2025.2517898","DOIUrl":"10.1080/17476348.2025.2517898","url":null,"abstract":"<p><strong>Introduction: </strong>For many years the major cause of morbidity and mortality in people with cystic fibrosis (PWCF) was lung disease, characterized by progressive airway inflammation, bacterial colonization and premature death. With the advent of highly effective modulator therapies (HEMT) many of the parameters predicting premature death have been beneficially altered with resultant predicted improvement in survival. It is unknown how much residual airway inflammation will persist in PWCF on HEMT, whether bacterial colonization will be eradicated and whether the beneficial effects decrease over times. In addition, a significant number of PWCF cannot avail of HEMT.</p><p><strong>Areas covered: </strong>We discuss pathogenesis of airways disease in CF, airway inflammation and bacterial colonization in PWCF on and off HEMT, and whether new anti-inflammatory strategies are required to decrease residual inflammation and improve bacterial eradication. We discuss the potential therapeutic options for those PWCF for whom HEMT are not an option.</p><p><strong>Expert opinion: </strong>PWCF on HEMT may expect prolonged survival but in many, particularly those in whom HEMT therapy was instituted after the onset of structural lung disease there will be persistent inflammation requiring further therapy.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"997-1015"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sang-Geon Cho, Sun-Joo Jang, Paul Heerdt, Stephanie L Thorn, Albert J Sinusas
{"title":"Early detection of lung injury and matrix metalloproteinase activation in ARDS could improve diagnostic and therapeutic strategies?","authors":"Sang-Geon Cho, Sun-Joo Jang, Paul Heerdt, Stephanie L Thorn, Albert J Sinusas","doi":"10.1080/17476348.2025.2515993","DOIUrl":"10.1080/17476348.2025.2515993","url":null,"abstract":"","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"899-901"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An overview of the recent trials of corticosteroids for severe community-acquired pneumonia.","authors":"Benjamin Edland, Grant W Waterer","doi":"10.1080/17476348.2025.2513518","DOIUrl":"10.1080/17476348.2025.2513518","url":null,"abstract":"<p><strong>Introduction: </strong>The use of corticosteroids in the setting of community-acquired pneumonia (CAP) remains controversial.</p><p><strong>Areas covered: </strong>Here, we review the evidence for and against corticosteroids in the setting of CAP with a particular focus on three recent randomized, placebo-controlled trials that have disparate results but significantly advance our knowledge in the field.</p><p><strong>Expert opinion: </strong>Current published data does not support widespread use of corticosteroids in CAP, with evidence this is more likely to cause harm than benefit. The use of hydrocortisone in a limited number of patients with respiratory failure of less than 24 h duration and a serum c-reactive protein > 200 mg/L may be supportable if a high dependency setting is available to address hyperglycemia. Disparate results and polarized positions among experts in the field will only be resolved by studies with tighter entry criteria, better definition of target groups, consideration of the infecting pathogen and therapeutic window for benefit.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"925-933"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nathália Leite Barbosa, Thaianne Rangel Agra Oliveira, Larissa Domingos Nóbrega, Thaíly Ticiane Fernandes Araújo, Sarah Rayanne Dos Santos Bezerra, Giovanna Miller Oliveira, Rebeca Monteiro Do Nascimento, Patrícia Angélica de Miranda Silva Nogueira, Alecsandra Ferreira Tomaz, Ana Tereza Do Nascimento Sales Figueiredo Fernandes
{"title":"Prevalence and characteristics of respiratory and cardiovascular sequelae in post-COVID-19 syndromes: a scoping review.","authors":"Nathália Leite Barbosa, Thaianne Rangel Agra Oliveira, Larissa Domingos Nóbrega, Thaíly Ticiane Fernandes Araújo, Sarah Rayanne Dos Santos Bezerra, Giovanna Miller Oliveira, Rebeca Monteiro Do Nascimento, Patrícia Angélica de Miranda Silva Nogueira, Alecsandra Ferreira Tomaz, Ana Tereza Do Nascimento Sales Figueiredo Fernandes","doi":"10.1080/17476348.2025.2515992","DOIUrl":"10.1080/17476348.2025.2515992","url":null,"abstract":"<p><strong>Introduction: </strong>Post acute and Long COVID-19 are public health issues, marked by persistent respiratory and cardiovascular symptoms such as dyspnea and palpitations. These complications often extend beyond the acute phase, affecting even individuals with mild or moderate COVID-19. This article reviews the clinical impact of long COVID-19 and emphasizes the need for a multidisciplinary approach to management.</p><p><strong>Areas covered: </strong>A comprehensive literature search was conducted through PubMed, Medline, CINAHL, SciELO, and LILACS to identify studies published up to 28 October 2024, reporting on respiratory and cardiovascular sequelae in long COVID-19. This review examines the prevalence and characteristics of persistent symptoms such as dyspnea, cough, and palpitations, as well as the associated risk factors and assessment methods.</p><p><strong>Expert opinion: </strong>Long COVID-19 represents a significant healthcare challenge, underscoring the need for standardized protocols for diagnosis and treatment. A multidisciplinary approach is crucial to address the diverse symptoms of affected patients. Future research should focus on understanding the underlying pathophysiology, and developing targeted therapeutic strategies to improve patient outcomes.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"935-953"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tim Takken, Tamara Ruuls, Mattiènne Van der Kamp, Bernardus Thio, Marco van Brussel, Erik H J Hulzebos
{"title":"An update on clinical recommendations for cardiopulmonary exercise testing in children with respiratory diseases.","authors":"Tim Takken, Tamara Ruuls, Mattiènne Van der Kamp, Bernardus Thio, Marco van Brussel, Erik H J Hulzebos","doi":"10.1080/17476348.2025.2547418","DOIUrl":"10.1080/17476348.2025.2547418","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiopulmonary exercise testing (CPET) is a diagnostic-integrated tool for evaluating cardiovascular, ventilatory, and metabolic functional limitations in children with respiratory diseases. Recently, novel applications have emerged, revealing dynamic abnormalities that may go unnoticed in standard static cardiac and pulmonary function tests. Given its clinical importance and novel research findings, updated recommendations are warranted.</p><p><strong>Areas covered: </strong>We conducted a narrative review based on a literature search up to April 2025. This review provides an update on the application of CPET in pediatric respiratory diseases, covering physiological differences to adults, non-traditional CPET metrics such as the oxygen uptake efficiency slope (OUES), tidal volume to inspiratory time ratio (VT/Ti), and recent reference values. Indications, contraindications, and standardized protocols are discussed, alongside emerging trends in CPET technology.</p><p><strong>Expert opinion: </strong>CPET is a potent tool for assessing, evaluating, and diagnosing pediatric respiratory diseases. Standardized protocols, age-specific reference values, and novel CPET parameters enhance clinical utility. Future research should refine interpretation, integrate artificial intelligence for data analysis, and facilitate CPET for younger children.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-15"},"PeriodicalIF":2.7,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}